Previous Article | Next Article 
Molecular and Cellular Biology, March 1999, p. 1775-1783, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cyclin D-CDK Subunit Arrangement Is Dependent on
the Availability of Competing INK4 and p21 Class Inhibitors
David
Parry,1
Daniel
Mahony,1
Ken
Wills,2 and
Emma
Lees1,*
DNAX Research Institute of Molecular and
Cellular Biology, Palo Alto, California 94304,1
and Canji Incorporated, San Diego, California
921212
Received 17 August 1998/Returned for modification 7 October
1998/Accepted 14 December 1998
 |
ABSTRACT |
The D-type cyclins and their major kinase partners CDK4 and CDK6
regulate G0-G1-S progression by contributing to
the phosphorylation and inactivation of the retinoblastoma gene
product, pRB. Assembly of active cyclin D-CDK complexes in response to
mitogenic signals is negatively regulated by INK4 family members. Here
we show that although all four INK4 proteins associate with CDK4 and
CDK6 in vitro, only p16INK4a can form stable, binary
complexes with both CDK4 and CDK6 in proliferating cells. The other
INK4 family members form stable complexes with CDK6 but associate only
transiently with CDK4. Conversely, CDK4 stably associates with both
p21CIP1 and p27KIP1 in cyclin-containing
complexes, suggesting that CDK4 is in equilibrium between INK4 and
p21CIP1- or p27KIP1-bound states. In agreement
with this hypothesis, overexpression of p21CIP1 in 293 cells, where CDK4 is bound to p16INK4a, stimulates the
formation of ternary cyclin D-CDK4-p21CIP1 complexes. These
data suggest that members of the p21 family of proteins promote the
association of D-type cyclins with CDKs by counteracting the effects of
INK4 molecules.
 |
INTRODUCTION |
Progress through the G1
phase of the mammalian cell cycle is regulated by the ordered
synthesis, assembly, and activation of distinct cyclin-CDK holoenzymes
(45, 46). Cyclins D1, D2, and D3 are up-regulated as cells
exit from quiescence and associate with their major kinase partners
CDK4 and CDK6 (3, 29, 32, 53). These two kinase molecules
are highly homologous and associate exclusively with the D-type cyclins
(3). Numerous studies have implicated cyclin D-CDK4-CDK6
complexes as key regulators of the cell cycle up to a hypothetical
point during late G1 (24, 25), the restriction
point, when hyperphosphorylation and inactivation of the retinoblastoma
tumor suppressor gene product, pRB, occur (37, 44).
In contrast to mitotic cyclin-CDK complexes, the D-type cyclins do not
automatically assemble into complexes with either CDK4 or CDK6. For
example, when overexpressed in NIH 3T3 cells in the absence of serum,
D-type cyclins and CDK4 do not interact efficiently (30).
Hence, assembly of D-type cyclins and CDK4 and CDK6 into functional
complexes in vivo is likely to depend on numerous factors, in
particular, synthesis rates and stability of the various components. Indeed, the D-type cyclins possess canonical PEST sequences near their
C termini and have short half-lives in vivo (4, 31).
Association of the D-type cyclins with CDK4 and CDK6 is also influenced
by the INK4 family of CDK inhibitors (p15INK4b,
p16INK4a, p18INK4c, and p19INK4d)
(9, 10, 12, 18, 42). INK4 polypeptides bind to the catalytic
subunits and inhibit the association of D-type cyclins (10,
38). Typically, human cell lines that lack functional pRB express
very high levels of p16INK4a (1, 35, 38). In
such cells, CDK4 and CDK6 do not interact with D-type cyclins but are
sequestered into long-half-life, binary complexes with
p16INK4a (38). These observations have led to a
simple model whereby INK4 family members compete with the D-type
cyclins for binding to their target CDKs, and uncomplexed D-type
cyclins are rapidly degraded.
Members of a second family of CDK-regulatory molecules
(p21CIP1, p27KIP1, and p57KIP2)
(8, 15, 22, 28, 40, 48) comprise a class of polypeptides thought to be broad-spectrum inhibitors of different cyclin-CDK complexes. The prototypic member is p21CIP1, a molecule
independently identified by several laboratories. Variously described
as a p53-regulated cell cycle inhibitor and a marker induced during
cellular senesence (7, 34), p21CIP1 was also
cloned biochemically by virtue of copurification with cyclin D1 from
mammalian cell extracts (52). In vitro, p21 family members
bind to and inhibit the kinase activities of many mammalian cyclin-CDK
complexes (16). Recently, evidence has emerged that in
addition to simply inhibiting kinase activity, members of the p21
family of molecules may have additional roles. For instance, in
overexpression studies, p21CIP1 seemed to play a role
during assembly of cyclin D-CDK complexes (20).
Aberrant accumulation of active cyclin D-CDK complexes and the
inappropriate phosphorylation of pRB are common events in a variety of
human tumors (11). Cyclin D1 becomes amplified or overexpressed in many different tumor types (5, 21).
Similarly, CDK4 is subject to amplification (17, 26, 41), as
well as to point mutations that render it insensitive to INK4
inhibition (50). However, of all the CDK inhibitors, only
p16INK4a has been shown convincingly to be a tumor
suppressor (19, 39). Consistent with this,
p16INK4a levels rise dramatically during cellular
senescence (2, 13, 36). In this work, we address the
mechanism of cyclin D-CDK assembly by examining specific biochemical
properties of individual CDK inhibitors and their associated target
molecules. The data suggest that the INK4 and p21 families of
CDK-regulatory polypeptides play antagonistic roles during the
formation of cyclin D-CDK4-CDK6 holoenzymes. Moreover, we find that the
p16INK4a tumor suppressor gene product is unique among the
INK4 group, as it alone forms stable complexes with both CDK4 and CDK6
under proliferative conditions, suggesting that this molecule is a
specialized member of the INK4 family.
 |
MATERIALS AND METHODS |
Cell culture.
CEM and ML1 cells were maintained in RPMI 1640 medium with 10% fetal calf serum (FCS); EL4, WI38, 293, and MCF7 cells
were maintained in Dulbecco's modified Eagle's medium (DMEM) with
10% FCS. For adenovirus infections, 293 cells were split from the stock culture and grown to ~80% confluence. Adenovirus supernatants, both AdVec control and recombinant Adp21CIP1
(49), were applied at multiplicities of infection of ~2.
Twenty-four hours postinfection, cells were harvested prior to lysis.
Antibodies.
Peptides corresponding to the C-terminal regions
of the following polypeptides were synthesized (Research Genetics),
coupled to keyhole limpet hemocyanin (Pierce), and injected into
rabbits (Pocono Rabbit Farms): murine-human cyclin D1 (CLACTPTDVRDVDI), murine-human cyclin D2 (CDPDQATTPTDVRDVDL), murine-human cyclin D3
(CGPSQTSTPTDVTAIHL), murine-human CDK4 (CALQHSYLHKEESDAE), murine-human CDK6 (CSQNTSELNTA), murine p15INK4b
(CGHRDIARYLHAATGD), human p15INK4b (CGHRDVAGYLRTATGD),
human p16INK4a (CARIDAAEG PSDIPD), murine
p18INK4c (CSLMEANGVGGATSLQ), human
p18INK4c (CSLMQANGAGGATNLQ), murine
p19INK4d (CQNLMDILQGHMMIPM), human
p19INK4d (CQDLVDILQGHMVAPL), and human p21CIP1
(CTDFYHSKRRLIFSKRKP). All peptide antisera were affinity
purified against the cognate immunogen (Sulfolink; Pierce).
Antibodies to glutathione-S-transferase (GST) fusion
proteins of murine p21CIP1 and human p27KIP1
were also raised. These were partially purified on protein A columns
(Pierce) and subsequently depleted of GST-reactive immunoglobulins by
passage over agarose-immobilized GST. Following purification, all sera
were either dialyzed against phosphate-buffered saline (PBS)-1 mM
dithiothreitol (DTT) plus 20% glycerol or covalently coupled to
protein A-Sepharose beads for use in immunoprecipitation analyses
(14). Dialyzed sera were stored at
20°C, and
antibody-bead slurries were maintained at 4°C. Antibody specificity
was confirmed with specific in vitro-translated products and by
immunoprecipitation, V8 proteolytic analysis, and Western blotting.
Gel filtration chromatography.
Gel filtration chromatography
was carried out by using a Superdex 200 HR 10/30 column with a
fast-performance liquid chromatography system (Pharmacia). Samples (500 µl) containing 5 to 10 mg of whole-cell extract were loaded onto the
column and separated in gel filtration buffer (50 mM HEPES [pH 7.5],
10 mM MgCl2, 150 mM NaCl) at a flow rate of 0.3 ml/min for
the first 5 ml, 0.4 ml/min for the next 10 ml, and then 0.5 ml/min for
the final 10 ml. The molecular mass standards (Sigma) used to calibrate
the column were blue dextran (2,000 kDa), thyroglobulin (669 kDa), apoferritin (443 kDa),
-amylase (200 kDa), alcohol dehydrogenase (150 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa)
and cytochrome c (12.4 kDa). The void volume of different columns was between 8 and 8.5 ml, and this volume was the point at
which fraction collection commenced. For each fractionation, 24 0.5-ml
fractions were collected. Typically, fractions 2 to 19 were used in
later experiments.
Immunoprecipitation and Western blotting analyses.
Cells
were washed once in PBS and lysed in Nonidet P-40 (NP-40) lysis buffer
(50 mM HEPES [pH 7.5], 1% NP-40, 150 mM NaCl, 1 mM DTT, aprotinin
[5 µg/ml], leupeptin [5 µg/ml], pepstatin [5 µg/ml],
Pefabloc [5 µg/ml]) at 4°C for 30 min. Lysates were then
clarified by centrifugation at 15,000 × g for 15 min.
For kinase assays, lysates were prepared by the addition of Tween 20 lysis buffer (50 mM HEPES [pH 7.5], 10 mM MgCl2, 150 mM
NaCl, 0.1% Tween 20, 1 mM DTT, 25 µM ATP, aprotinin [5 µg/ml],
leupeptin [5 µg/ml], pepstatin [5 µg/ml], Pefabloc [5
µg/ml]), followed by passage through a 19-gauge hypodermic needle
and two rounds of freeze-thawing on dry ice. Immunoprecipitations were
performed with 50 µl of bead-immobilized antibodies (20% slurries).
Peptide blocks were performed by preincubating 5 µg of cognate
peptide with antibody beads at 30°C for 30 min prior to the addition
of lysate. Typically 500 to 1,000 µg of whole-cell extract was used in standard immunoprecipitations. Immune complexes were collected by
rocking for 2 h at 4°C, followed by extensive washing with ice-cold lysis buffer. For Western blotting analysis, samples were
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon P membrane (Millipore). Membranes were probed with primary antibodies diluted in PBS-0.2% Tween 20-5% milk powder, either singly or in combination. Complexes were detected with horseradish peroxidase-linked secondary serum (Amersham) and enhanced chemiluminescence (ECL; Amersham).
Immunodepletions.
Whole-cell extracts were prepared with
NP-40 lysis buffer and subjected to five rounds of immunodepletion,
using either normal rabbit immunoglobulin or a combination of
anti-p21CIP1 (
p21CIP1) and
p27KIP1 antibodies immobilized on beads. Following
depletion, supernatants were immunoprecipitated with specific antisera
as required.
In vitro binding assays.
In vitro translation products were
generated by using a coupled transcription-translation system (TNT;
Promega) according to manufacturer's protocols. Equal amounts
(typically 5 µl) of two freshly generated in vitro-translated
products were mixed and incubated at 30°C for 30 min. The mixture was
then diluted with 1 ml of lysis buffer containing 1% NP-40, 50 mM
HEPES (pH 7.5), 500 mM NaCl, 3% bovine serum albumin, and protease
inhibitors, followed by centrifugation at 16,000 × g for 10 min to remove any denatured material. A 950-µl aliquot of the
supernatant was transferred to a fresh tube containing INK4-specific
antibody-bead slurry. The sample was then processed in the same way as
a normal immunoprecipitation.
Pulse-chase analyses.
Approximately 107 cells
per time point were washed in DMEM without methionine supplemented with
10% dialyzed FCS and incubated in similar medium for 30 min at 37°C.
Cells were pulsed-labelled for 4 h with 35S cell
labelling mix (Amersham) at 50 to 100 µCi/ml and then washed with
warm PBS before being placed in complete DMEM. Cells were lysed as
described above at hourly time points. Lysates were precleared overnight at 4°C with normal rabbit immunoglobulin and killed Staphylococcus aureus. Immunoprecipitations were performed
by incubating lysates with immobilized antibodies, and immune complexes were washed and separated by SDS-PAGE. Immunoprecipitated proteins were
visualized by fluorography using Amplify (Amersham).
Preparation of bacterially expressed recombinant protein.
For use in CDK4 kinase assays, a C-terminal fragment of human RB (amino
acids 773 to 928) fused to GST was utilized as an in vitro substrate
(32). Briefly, BL21(DE3)pLysS Escherichia coli
transformed with pGEX-RBCT were induced at room temperature with 0.1 mM
IPTG (isopropyl-
-D-thiogalactopyranoside) for 3 h. Bacterial pellets were lysed by the addition of ice-cold Tween 20 lysis
buffer (50 mM HEPES [pH 7.5], 10 mM MgCl2, 150 mM NaCl, 0.1% Tween 20, 1 mM DTT, 25 µM ATP, aprotinin [5 µg/ml],
leupeptin [5 µg/ml], pepstatin [5 µg/ml], Pefabloc [5
µg/ml]) and sonication. Soluble fusion proteins were purified by
affinity chromatography on glutathione-agarose and eluted with 20 mM
reduced glutathione. Positive fractions containing the fusion protein
were pooled and dialyzed overnight against kinase assay buffer (50 mM
HEPES [pH 8.0], 10 mM MgCl2, 2.5 mM EGTA, 1 mM DTT, 50 µM ATP) plus 20% glycerol. Dialyzed GST RB was dispensed as aliquots
and stored at
80°C. GST fusion proteins that were to be used as
immunogens were dialyzed against PBS containing 1 mM DTT and stored at
80°C until required.
Kinase assays.
Kinase assays were carried out according to
an adaptation of a previously described protocol (30) using
the GST RB C-terminal (GST-RBCT) construct described above as a
substrate. Cells were lysed in Tween 20 lysis buffer and
immunoprecipitated as described above. Immune complexes were washed
three times with Tween 20 lysis buffer and twice with kinase reaction
buffer (50 mM HEPES [pH 8.0], 10 mM MgCl2, 2.5 mM EGTA, 1 mM DTT, 50 µM ATP). GST RB (2.5 µg) and 10 µCi of
[
-32P]ATP (Amersham) were added to each sample, and
the volume was made up to 50 ml with kinase reaction buffer. Reactions
were incubated at 30°C for 20 min and stopped by adding 6× SDS
sample buffer. Phosphorylated products were resolved on an SDS-12%
polyacrylamide gel and analyzed by autoradiography at room temperature.
 |
RESULTS |
CDK4 and CDK6 have different gel filtration profiles.
We have
previously shown by gel filtration that CDK6 from CEM cells is present
in three major complexes, implying biochemical regulation of CDK6
interactions within cells (27). A 450-kDa complex comprises
CDK6 complexes with chaperone molecules such as HSP90 and CDC37. A
minor complex that migrates at approximately 150 to 170 kDa contains
cyclin D-CDK6 complexes. When assayed in vitro with a GST RB substrate,
this fraction of CDK6 is kinase active. Finally, CDK6 is present in a
smaller, ~55-kDa complex that comprises independent binary complexes
of CDK6 with INK4 proteins, as well as potentially monomeric forms of
the kinase. To examine whether CDK4 regulation was similar to that of
CDK6, we extended these analyses in a range of cell lines (Table
1) and compared the properties of CDK4
and CDK6 by gel filtration.
Whole-cell extracts were prepared from EL4 cells, a T-lymphoma cell
line that expresses roughly equivalent levels of both
CDK4 and CDK6 as
well as all three D-type cyclins (
27) (Table
1). These
extracts were fractionated by gel filtration on Superdex
200 and
immunoprecipitated with

CDK4 or

CDK6 serum. The immune
complexes
were then separated by SDS-PAGE and immunoblotted with
the
precipitating sera to detect the independent complexes. As
expected,
the presence of CDK6 in three complexes was revealed
(Fig.
1A). In contrast, CDK4 from these cells
was present in only
two major complexes, of approximately 450 and 170 kDa (Fig.
1B).
CDK4 complexes corresponding to the 55-kDa CDK6 complex
were barely
detectable. Identical profiles were obtained when
fractionated
whole-cell extract from EL4 cells was directly
immunoblotted with

CDK4 or

CDK6 serum, suggesting that the
observed difference
was not due to an inability of our CDK4 serum to
recognize any
putative 55-kDa CDK4 complexes (data not shown). The same
Western
blots were subsequently reprobed with

D1 and

D2 sera,
singly
or in combination. Both CDK4 and CDK6 were found to associate
with these cyclins in complexes of approximately 150 to 170 kDa
(Fig.
1C and D). The faint band visible above cyclin D1 in Fig.
1C
corresponds to the mouse-specific, modified form of this molecule
(p37
mD1) (
3,
31). In agreement with previous findings (
6,
47), the larger, 450-kDa CDK4 complex was found to contain CDC37
and HSP90 (data not shown). In reciprocal experiments,

D2 serum
was
used to immunoprecipitate fractionated EL4 extract. Following
SDS-PAGE,
immune complexes were immunoblotted with

CDK4 and

CDK6
sera (Fig.
1E). CDK4- and CDK6-containing complexes detected by
this approach were
found to be approximately 150 to 170 kDa in
size, which is in agreement
with the results achieved via precipitation
through the kinase partner.
When reprobed with

D2 serum, it was
apparent that all of the
detectable cyclin D2 was eluted in such
complexes (Fig.
1F). Similar
experiments with a variety of cell
lines gave comparable results for
all three D-type cyclins (data
not shown).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 1.
Gel filtration analysis of CDK4 and CDK6. EL4 whole-cell
extract was separated and immunoprecipitated with CDK6 serum (A) or
CDK4 serum (B) followed by blotting with the precipitating antiserum
to reveal the different complexes. Blots were reprobed with D1 and
D2 sera (C and D). (E) Column fractions were immunoprecipitated with
D2 serum and immunoblotted with a mixture of CDK4 and CDK6
sera. This blot was then reprobed with D2 (F). (G) CDK4 kinase
assays on similar EL4 fractions, with GST-RBCT used as a substrate. M,
molecular mass markers; IP, immunoprecipitation.
|
|
Since the majority of the cyclin D-CDK4 complexes were
indistinguishable in size from CDK6 complexes previously demonstrated
to be kinase competent in vitro (
27), we wanted to confirm
that
the 150- to 170-kDa CDK4 complexes were active. Following gel
filtration, CDK4 immunocomplex kinase assays were performed with
the
GST RBCT construct (
32) as a substrate. CDK4 kinase activity
was found to correlate with elution of detectable cyclin D-CDK4
complexes in these cells (Fig.
1G). Therefore, although broadly
similar, CDK4 and CDK6 gel filtration profiles from EL4 cell extract
exhibit a clear difference, as CDK4 does not form detectable 55-kDa
complexes analogous to the CDK6-INK4 moiety previously identified
in
proliferating
cells.
Members of the INK4 family differ in ability to form complexes with
both CDK4 and CDK6.
To examine CDK4 association with INK4 family
members, we surveyed INK4-CDK4 and -CDK6 interactions in a variety of
cell lines by using specific
INK4 sera (Table
2). Representative samples of the data
are shown in Fig. 2A. Significantly, only
p16INK4a was found to form steady-state complexes with both
CDK4 and CDK6, as shown by immunoprecipitation from WI38 diploid
fibroblasts. In contrast, p15INK4b, p18INK4c,
and p19INK4d immunoprecipitations from asynchronously
growing cells contained CDK6 but no detectable CDK4. Under similar
conditions, CDK4 was detected in
D2 complexes, suggesting that CDK4
functions normally in these cells (Fig. 2A). To address the
stoichiometries of these interactions, whole-cell extracts were
fractionated by gel filtration and subjected to immunoprecipitation
with specific
INK4 sera. Binary complexes of p16INK4a
with CDK4 and p16INK4a with CDK6 were present in WI38
lysates (Fig. 2C). However, when assayed by this method the other INK4
family members formed 55-kDa complexes with CDK6 only (Fig. 2B, D, and
E). The blots were reprobed with the precipitating antiserum to reveal
the elution profiles of the various INK4 molecules. In the cell lines
tested, all four INK4 family members coeluted with CDK4 or CDK6 in
complexes of ~55 kDa. INK4 proteins were not detected in complexes
outside of this size range (data not shown). Overall, an interesting
correlation between absence of p16INK4a and lack of 55-kDa
CDK4 complexes was observed, suggesting that the majority of INK4
family members interact with CDK6 but not CDK4 under these conditions.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 2.
INK4-CDK4 and INK4-CDK6 interactions. (A) Cell lysates
from EL4, WI38, and CEM cell lines were subjected to
immunoprecipitation with specific INK4 serum with (+) or without
( ) peptide block as indicated. Anti-CDK4, CDK6, and D2
immunoprecipitations were included as controls. Immune complexes were
separated by SDS-PAGE and immunoblotted with a mixture of CDK4 and
CDK6 sera. Similar analyses were then performed on fractionated
whole-cell extracts. (B) Fractionated EL4 extract was
immunoprecipitated with p15INK4b and immunoblotted with
CDK4- CDK6. (C) Similarly, WI38 lysate was fractionated and
immunoprecipitated with p16INK4a, followed by blotting
with CDK4- CDK6. Likewise, EL4 and CEM fractions were
immunoprecipitated with p18INK4c (D) and
p19INK4d (E), respectively, and probed with
CDK4- CDK6. IP, immunoprecipitation.
|
|
All INK4 family members associate with CDK4 and CDK6 in vitro.
The differences in CDK4 and CDK6 binding found in vivo were unexpected,
as members of the INK4 family are highly homologous in pairwise
comparisons. One explanation for the data is that p15INK4b,
p18INK4c, and p19INK4d do not bind CDK4.
Indeed, p18INK4c was originally reported to be a specific
CDK6 inhibitor (9). We performed in vitro binding assays
using [35S]methionine-labelled, in vitro translates of
all INK4 family members and CDK4 and CDK6. Cyclin D1 and CDK2 were used
as negative controls for interaction. Under these conditions, all four
INK4 family members bound CDK4 and CDK6 with similar affinities (Fig. 3A). Samples of cyclin D1, CDK2, CDK4,
and CDK6 in vitro translates were run on a separate gel to control for
input levels (Fig. 3B). Viewed in combination with the
immunoprecipitation data, these data provide evidence that all INK4
proteins are capable of association with both CDK4 and CDK6 in vitro.
However, detectable, steady-state complexes between
p15INK4b, p18INK4c, or p19INK4d and
CDK4 do not accumulate in proliferating cells.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 3.
In vitro binding of INK4 inhibitors to CDK4 and CDK6.
(A) Freshly prepared D1, CDK2, CDK4, and CDK6 in vitro translates were
mixed with individual INK4 in vitro translates, as indicated (A).
Complexes were immunoprecipitated using specific antisera, separated by
SDS-PAGE in a 12% gel, and visualized by autoradiography. (B) Aliquots
of input in vitro translates were separated on another gel as a loading
control.
|
|
CDK4 forms unstable complexes with p18INK4c in
vivo.
To test the hypothesis that the stability of INK4-CDK4 and
-CDK6 interactions differ among family members, we performed
pulse-chase experiments with two cell lines, EL4 and ML1. Cells were
labelled with [35S]methionine and chased in
nonradioactive medium over a 4-h time course. Lysates were prepared,
and
p18INK4c immunoprecipitations were performed at
hourly time points. Under these conditions, newly synthesized CDK6 and
CDK4 were found to associate with p18INK4c at time zero,
indicating that both kinases do indeed associate with
p18INK4c, which confirms the in vitro binding experiments.
However, during the chase in nonradioactive medium,
35S-labelled CDK4 disappeared rapidly from
p18INK4c complexes in both cell lines analyzed (Fig.
4), whereas CDK6 remained associated with
p18INK4c throughout the duration of the experiment. In
control experiments, both CDK4 and CDK6 were found to possess long
half-lives when measured by specific immunoprecipitation (data not
shown).

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 4.
Stability of p18INK4c-CDK complexes.
Logarithmically growing cultures of EL4 (A) and ML1 (B) cells were
pulse-labelled with [35S]methionine and chased with
medium containing unlabelled amino acids. At the time points indicated,
cell extracts were prepared and subjected to immunoprecipitation (IP)
with specific p18INK4c sera. Immune complexes were
separated by SDS-PAGE in a 12% gel.
|
|
CDK4 is found in steady-state, ternary complexes with cyclin D and
p21CIP1-p27KIP1.
CDK4 does not form stable
complexes with p18INK4c in EL4 and ML1 cells. In other
metabolic labelling experiments, newly synthesized CDK4 was also
detected in
p15INK4b and
p19INK4d
immunoprecipitations (data not shown), implying that CDK4 forms similar
short-lived complexes with these INK4 molecules. However, CDK4 is
detectable by Western blotting as one component of a 150- to 170-kDa
moiety, suggesting that in this context CDK4 is part of a stable
complex. The D-type cyclins also contribute to this complex (Fig. 1).
Other likely candidates for cyclin D-CDK interacting proteins were
members of the p21 family of CDK inhibitors. To examine the
distribution of p21 family molecules, EL4 whole-cell extracts were
fractionated by gel filtration and immunoprecipitated with specific
p21CIP1 or
p27KIP1 sera. Immune complexes
were separated by SDS-PAGE and immunoblotted with
D2 and
CDK4
sera.
p21CIP1 immunoprecipitations revealed a 150- to
170-kDa, p21CIP1-D2-CDK4 complex (Fig.
5A, upper panel). When reprobed with
p21CIP1, it was apparent that p21CIP1 was
not detectable in complexes outside of this molecular mass range (Fig.
5A, lower panel). Virtually identical results were obtained for
p27KIP1-containing complexes when
p27KIP1
serum was used as the precipitating antibody (Fig. 5B). Furthermore, similar profiles were obtained when p21CIP1-D2-CDK6 and
p27KIP1-D2-CDK6 complexes were analyzed by gel filtration
(data not shown). To confirm the ternary nature of these complexes,
similar gel filtrations were performed, and fractions were
immunoprecipitated with
D2 sera, separated by SDS-PAGE, and
immunoblotted with
p21CIP1 (Fig. 5C, upper panel) or
p27KIP1 (Fig. 5C, lower panel). Thus, the majority of
D-type cyclins and p21CIP1 and p27KIP1 are
associated in readily detectable 150- to 170-kDa complexes. To rule out
the possibility that p21CIP1 and p27KIP1 reside
in the same complex simultaneously,
p21CIP1
immunoprecipitations were immunoblotted with
p27KIP1
sera, and vice versa. We could find no evidence for such quarternary interactions (data not shown). To estimate the fraction of the 150- to
170-kDa cyclin D-CDK complex that was associated with p21 family
members, immunodepletion experiments using lysates prepared from two
cell lines, EL4 (T lymphoma) and MCF7 (breast adenocarcinoma), were
performed. Whole-cell extracts were subjected to immunodepletion with
either normal rabbit immunoglobulin G or a combination of both
p21CIP1 and
p27KIP1 sera. The depleted
extracts were then divided equally and immunoprecipitated with
D1-D2-D3,
p21CIP1-p27KIP1, or normal
rabbit immunoglobulin G. The resulting immune complexes were separated
by SDS-PAGE and immunoblotted with a mixture of
D1-D2-D3 sera.
Significantly, all three D-type cyclins were removed from EL4 and MCF7
extracts upon immune depletion of p21CIP1 and
p27KIP1 (Fig. 5D). There was no diminution of the D-type
cyclin signal in
D1-D2-D3 or
p21CIP1-p27KIP1 immunoprecipitations
performed with mock-depleted extracts of either cell line. Although not
quantitative, these data strongly suggest that the majority of
detectable cyclin D-CDK complexes contain either p21CIP1 or
p27KIP1.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of p21CIP1 and p27KIP1
by gel filtration. EL4 whole-cell extracts were prepared and
fractionated over Superdex 200. (A) Fractions were immunoprecipitated
with p21CIP1 sera and immunoblotted with a mixture of
D1- D2 and CDK4 sera (upper panel). The blot was then reprobed
with p21CIP1 (lower panel). (B) Immunoprecipitates from
a similar EL4 fractionation using p27KIP1 sera were
immunoblotted in the same way. (C) -D2 serum was used to
immunoprecipitate complexes following gel filtration. After SDS-PAGE,
the immune complexes were immunoblotted with sera specific for
p21CIP1 (upper panel) or p27KIP1 (lower panel).
(D) Mock-depleted and
p21CIP1- p27KIP1-immunodepleted extracts
of EL4 and MCF7 cells were subjected to immunoprecipitation with
D1-D2-D3, p21CIP1- p27KIP1 or normal
rabbit serum, as indicated. Immune complexes were separated by SDS-PAGE
and immunoblotted with a mixture of D1/D2/D3 sera. IP,
immunoprecipitation.
|
|
Both p16INK4a and p21CIP1 form stable
complexes with CDK4.
In pulse-chase experiments, CDK4 has a
long-half-life interaction with p16INK4a (38),
an observation supported by the relative ease with which both CDK4 and
CDK6 can be detected in
p16INK4a immunoprecipitations.
Other INK4 molecules seem less able to form stable complexes with CDK4
(Fig. 2 and 4) in the cell lines tested. Conversely, the abundance of
CDK4 present in steady-state p21CIP1 complexes implies that
cyclin D-CDK4-p21CIP1 ternary complexes have long
half-lives. To compare the duration of CDK4 in p16INK4a-
and p21CIP1-containing complexes, we performed pulse-chase
analyses with WI38 primary fibroblasts, a cell line that expresses both
proteins (Table 1). At each time point, lysates were prepared and
immunoprecipitated with antisera specific for p16INK4a or
p21CIP1. The resulting immune complexes were separated by
SDS-PAGE, and the turnover rate of coprecipitated CDK4 was assessed by fluorography.
As expected,

p16
INK4a immunoprecipitations contained
35S-labelled CDK4 and CDK6 throughout the time course, with
the half-lives
of these complexes being in excess of 4 h (Fig.
6A), which is
in good agreement with
previous findings (
36,
38). Using

p21
CIP1
sera to measure the stability of associated CDK4 revealed a stable,
associated band migrating at approximately 33 kDa during SDS-PAGE
(Fig.
6B). Since CDK2 is also known to associate with p21
CIP1
(
8) and has a mobility similar to that of CDK4 in SDS-PAGE,
we wanted to definitively demonstrate the stability of CDK4 in
such
complexes. The pulse-chase was repeated, and the resulting

p21
CIP1 immune complexes were denatured and subsequently
reimmunoprecipitated
with

CDK4 sera. As shown in Fig.
6C, CDK4
molecules reimmunoprecipitated
from p21
CIP1 complexes have
a half-life similar to those coprecipitated with
p16
INK4a.
In similar pulse-chases performed with other cell lines, CDK4
was
repeatedly observed to be stable in p21
CIP1 complexes (data
not shown). The stability of CDK4 in the context
of ternary complexes
with D-type cyclins and p21
CIP1 suggests that
p21
CIP1 affects the distribution of CDK4 between INK4 and
cyclin D-associated
states. Significantly, p21
CIP1
consistently demonstrated a half-life of approximately 1 to 2
h,
substantially shorter than the half-lives observed for
p16
INK4a and p18
INK4c.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
Relative stabilities of p16INK4a and
p21CIP1-bound CDK4. Logarithmically growing cultures of
WI38 cells were pulse-labelled with [35S]methionine and
chased with medium containing unlabelled amino acids. At the time
points indicated, extracts were prepared and immunoprecipitated with
specific p16INK4a (A) or p21CIP1 (B)
sera. Immune complexes were separated by SDS-PAGE in a 12% gel. (C)
Metabolically labelled CDK4 reimmunoprecipitated from an
p21CIP1 pulse-chase. IP, immunoprecipitation.
|
|
CDK4 forms stable complexes with p16INK4a and
p18INK4c in cells that lack cyclin
D-CDK4-p21CIP1 ternary complexes.
Pulse-chase analyses
with WI38 cells suggested that p21 family members influence the
interactions of CDK4 via competitive stabilization, thus antagonizing
the effects of INK4 molecules. We were interested in examining the
distribution of CDK4 in cells without ternary cyclin
D-CDK-p21CIP1 complexes, such as human cell lines that lack
functional pRB (4). In such cells, CDK4 and CDK6 are found
associated with p16INK4a, and 293 is a cell line that
conforms to this paradigm. 293 cells express p18INK4c and
undetectable levels of both p21CIP1 and p27KIP1
(data not shown) on a background of extremely high p16INK4a
expression. This allowed analysis of different INK4-CDK4 interactions in a setting independent of p21CIP1.
To confirm the lack of detectable cyclin D-CDK-p21
CIP1
complexes in 293 cells, whole-cell extracts were prepared and
immunoprecipitated
with a variety of specific antisera. Immune
complexes were separated
by SDS-PAGE and immunoblotted with

CDK4 and

CDK6 sera. As expected,
CDK4 and CDK6 were not detectable in

D1-D2-D3 or

p21
CIP1-p27
KIP1 immune
complexes. Both kinases were present at high levels in

p16
INK4a immune complexes. Significantly,

p18
INK4c immune complexes were found to contain both
CDK6 and CDK4 (Fig.
7A). To establish
whether CDK4 forms long-lived complexes with
p18
INK4c under
these conditions, pulse-chase experiments were performed
with

p16
INK4a and

p18
INK4c sera. Consistent
with the immunoblot analysis, CDK4 was found
to form long-half-life
complexes with both p16
INK4a and p18
INK4c in
these cells (Fig.
7B and C).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 7.
CDK4 complexes in 293 cells. (A) 293 whole-cell extract
was immunoprecipitated with the antisera shown. Immune complexes were
separated by SDS-PAGE and immunoblotted with a combination of CDK4
and CDK6 sera. Asynchronously growing cultures of 293 cells were
pulse-labelled with [35S]methionine and chased with
medium containing unlabelled amino acids. At the time points indicated,
cell extracts were prepared and immunoprecipitated with specific
p16INK4a (B) or p18INK4c (C) sera. Immune
complexes were separated by SDS-PAGE in a 12% gel. IP,
immunoprecipitation.
|
|
Overexpression of p21CIP1 in 293 cells restores
p21CIP1-cyclin D-CDK4 ternary complexes.
The
experiments outlined above demonstrate that CDK4 contributes to several
independent complexes within cells and suggest that CDK4 may be
involved in a dynamic equilibrium between INK4-bound and
p21CIP1- or p27KIP1-bound states. To test this
hypothesis, 293 cells were infected with recombinant adenovirus vectors
expressing p21CIP1 under the control of a cytomegalovirus
promoter (Adp21CIP1), or with vector control viruses
(AdVec) (49). At 24 h postinfection, lysates were
prepared and equivalent amounts were subjected to immunoprecipitation
with
D2,
p21CIP1, or normal rabbit serum. Following
SDS-PAGE, the immune complexes were immunoblotted with
D2 sera. In
AdVec-infected lysates, low levels of cyclin D2 were detected in the
D2 immunoprecipitate, and no cyclin D2 was detectable in
p21CIP1 immunoprecipitates (Fig.
8A). Following infection with
Adp21CIP1, the total level of cyclin D2 detected in
D2
immune complexes appeared elevated, suggesting that the introduction of
p21CIP1 affected the steady-state levels of this protein
(Fig. 8A). Significantly, in the
p21CIP1
immunoprecipitate from Adp21CIP1-infected lysate, cyclin D2
was present at a level similar to that seen in the adjacent
D2
immune complex, providing evidence that the majority of the cyclin D2
present in these cells was now associated with p21CIP1.
Next, we tested for the presence of CDK4 and p21CIP1 in
D2 and
D3 immunoprecipitates from similarly infected lysates. As
expected, in AdVec-infected cells no CDK4 was detectable in
D2 or
D3 immune complexes, whereas in lysate prepared from
Adp21CIP1 infected cells, CDK4 was efficiently
coimmunoprecipitated with cyclins D2 and D3 (Fig. 8B, upper panel).
Aliquots of whole-cell extract separated on the same gel demonstrate
that equivalent levels of CDK4 were present in both lysate
preparations. The blot was subsequently reprobed with
p21CIP1 sera (Fig. 8B, lower panel). As expected,
p21CIP1 was readily detected in Adp21CIP1- but
not AdVec-infected whole-cell extracts. Significantly, in Adp21CIP1 lysates, p21CIP1 was
coimmunoprecipitated with cyclin D2-CDK4 and cyclin D3-CDK4 complexes.
These data suggest that p21CIP1 is able to stimulate the
formation of cyclin D-CDK4-p21CIP1 ternary complexes, even
in the presence of excess p16INK4a. To confirm this,
whole-cell extract prepared from Adp21CIP1-infected 293 cells was fractionated by gel filtration and immunoprecipitated with
p21CIP1 sera. Immune complexes were separated by
SDS-PAGE and immunoblotted with
D2. Cyclin D2 was found associated
with p21CIP1 in a 150- to 170-kDa complex (Fig. 8C), which
is in good agreement with similar complexes detected previously in EL4
cells (Fig. 5).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 8.
Stimulation of cyclin D-CDK4 interaction by
p21CIP1. (A) 293 cells were infected with AdVec or
Adp21CIP1 adenoviruses, and lysates were immunoprecipitated
with D2, p21CIP1, or normal rabbit sera ( NR), as
indicated. Following SDS-PAGE, the immune complexes were probed with
D2 sera. (B) Similar infections were immunoprecipitated with D2,
D3, or normal rabbit sera. Immune complexes were separated by
SDS-PAGE alongside equivalents of whole-cell extract prepared from the
same samples. Following transfer, the membrane was immunoblotted with
CDK4 serum (upper panel) or p21CIP1 serum (lower
panel). (C) Adp21CIP1 293 cell lysate was separated on
Superdex 200. Fractions were collected and immunoprecipitated with
p21CIP1 sera. Immune complexes were separated by
SDS-PAGE and immunoblotted with D2 serum. IP, immunoprecipitation.
|
|
 |
DISCUSSION |
Gel filtration analyses of CDK4 and CDK6.
Both CDK4 and CDK6
form large multimeric complexes with chaperone molecules such as HSP90
and CDC37 that elute at ~450 kDa following gel filtration (6,
27, 47). Similarly, both kinases coelute with the peak of cyclin
D in complexes with a molecular mass of 150 to 170 kDa that are capable
of efficiently phosphorylating a GST RB substrate in vitro. A major
difference between the CDK4 and CDK6 gel filtration profiles was the
apparent lack of a 55-kDa CDK4 complex. We had previously demonstrated
that the 55-kDa CDK6 complex comprises CDK6-p19INK4d
complexes (27). The gel filtration observations implied that CDK4 did not associate with the INK4 proteins present in the cell lines
analyzed. Consistent with this, CDK4 was not found in
p15INK4b, p18INK4c, or p19INK4d
immune complexes isolated from a variety of cells, indicating that
although these inhibitors bound CDK6, they did not form complexes with
CDK4 that were detectable on Western blots. A common feature of the
immortalized cell lines analyzed is a lack of p16INK4a
expression. When we examined WI38 primary diploid fibroblasts, CDK4 was
identified in association with p16INK4a in 55-kDa complexes
that had properties similar to those of the various 55-kDa CDK6-INK4
complexes. This correlation suggests that p16INK4a alone
can titrate CDK4 into inactive binary complexes in asynchronously growing cells.
INK4-CDK4 interactions.
The INK4 protein,
p18INK4c, was originally described as a CDK6-specific
inhibitor because of a lack of association with CDK4 in CEM cells
(9). However, p18INK4c overexpression is
sufficient to arrest cells that express CDK4 as well as CDK6 in a
pRB-dependent manner, implying that p18INK4c is capable of
inhibiting the activity of CDK4 under certain circumstances (9,
18). The apparent inability of certain INK4 family members to
bind CDK4 in vivo is surprising, since in vitro, all four INK4 family
members associate with CDK4 and CDK6 equally well (Fig. 3). When we
analyzed interactions between newly synthesized components in
pulse-chase experiments, it became apparent that INK4 molecules such as
p18INK4c do indeed associate with CDK4 in cells, but such
complexes are short-lived in comparison to analogous CDK6-containing
complexes. The transient nature of p18INK4c-CDK4
association in these cells provides a possible explanation for the lack
of detectable interactions on Western blots. Significantly, when we
examined p18INK4c interactions in cell lines such as 293 that lack cyclin D-CDK complexes, p18INK4c was found
associated with both CDK4 and CDK6 in stable binary complexes
indistinguishable from similar p16INK4a complexes (Fig. 7).
It is possible, therefore, that cellular context influences the
distribution of CDK4 and CDK6, with CDK4 being particularly sensitive
to changes in subunit concentration. The exact mechanism that
determines the half-lives of the different INK4-CDK4 complexes is
unclear at present, although it seems likely that CDK4 interactions are
strongly influenced by intracellular levels of D-type cyclins and p21
family members.
p21CIP1 as a holoenzyme stabilizer.
Although CDK4
does not normally form long-half-life associations with
p18INK4c, it is found in steady-state complexes containing
D-type cyclins in a variety of proliferating cell lines that retain
functional pRB (Fig. 1). Upon analysis, such complexes were also found
to contain p21 family members (Fig. 5). Moreover, following
immunodepletion experiments it was apparent that the majority of cyclin
D-CDK4 complexes are associated with p21CIP1 and
p27KIP1. These findings extend previous observations
(20) and imply that all detectable cyclin D-CDK complexes in
asynchronously growing cells are associated with either
p21CIP1 or p27KIP1 in 150- to 170-kDa complexes
that are kinase active (Fig. 1G) (33). Additionally,
pulse-chase analyses demonstrated that CDK4 has a long-half-life
interaction with complexes containing p21CIP1 (Fig. 6),
suggesting that p21 family members might influence ternary cyclin D-CDK
interactions via stabilization. In agreement with this, expression of
p21CIP1 can reconstitute detectable cyclin
D-CDK4-p21CIP1 ternary complexes in 293 cells, even in the
presence of excess p16INK4a (Fig. 8). We attempted to
discover whether enforced expression of p21CIP1 led to a
concomitant decrease in the level of p16INK4a-CDK4 or
p18INK4c-CDK4 complexes, but were unable to definitively
demonstrate such a decrease by immunoprecipitation-Western blot
analyses or pulse-chase approaches (data not shown). It is likely that
the extremely high level of INK4 activity (p16INK4a in
combination with p18INK4c) in 293 cells continually
interferes with cyclin D-CDK-p21CIP1 assembly, resulting in
a process that is detectable but intrinsically inefficient. We estimate
that the majority of CDK4 remains associated with
p16INK4a-p18INK4c in this experimental system.
Also, because p21CIP1 can interact with many other
cyclin-CDK complexes, the specific concentration available to
contribute to cyclin D-CDK assembly may actually be very low.
Both p16
INK4a and p18
INK4c are very stable
molecules. In contrast, p21
CIP1 and cyclin D1 demonstrate
significantly shorter half-lives. Since
the pool of metabolically
labelled CDK4 associated with p21
CIP1-cyclin D complexes
remains relatively constant during pulse-chase
experiments, the cyclin
D and p21
CIP1 components must be continually replaced by
newly synthesized,
unlabelled molecules during the time course.
Therefore, constant
synthesis of p21
CIP1 may be required to
allow accumulation of ternary complexes in
the presence of competing
INK4 family members. Consistent with
this, many different mitogenic
signals induce expression of p21
CIP1 as well as members of
the type D cyclin family during the G
1 phase of the cell
cycle (
23,
43,
51). Taken together, these
data suggest that
during normal proliferation, p21 family members
antagonize the
inhibitory threshold function of the INK4 family,
by stabilizing
ternary cyclin D-CDK-p21
CIP1 complexes in
vivo.
Subunit arrangement and tumorigenesis.
CDK inhibitors play
pivotal regulatory roles during the mammalian cell cycle by restraining
the activity of cyclin-CDK complexes that might otherwise lead to
inappropriate hyperphosphorylation of the RB tumor suppressor gene
product. Because of this, all CDK inhibitors have been considered as
candidate tumor suppressor genes. However, data compiled by numerous
research groups from many different tumor types have demonstrated that
p16INK4a alone is commonly affected in human cancers. The
apparent inability of INK4 family members other than
p16INK4a to suppress cyclin D-CDK4 association during
normal proliferation, coupled with observations that p21 family members
promote the formation of active cyclin D-CDK4 complexes during a
mitogenic response, provides potential explanations as to why
p16INK4a alone is specifically targeted during tumorigenesis.
 |
ACKNOWLEDGMENTS |
We thank members of the Lees, McMahon, and Bolen laboratories for
thoughtful comments and suggestions; in particular we thank Frances
Shanahan, Wolfgang Seghezzi, Wouter Korver, Douglas Woods, and Michael
Tomlinson for critical reading of the manuscript. Also, we are grateful
to Maribel Andonian and Gary Burget for assistance with graphics.
DNAX Research and Canji Incorporated are supported by Schering Plough Corporation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: DNAX Research
Institute of Molecular and Cellular Biology, 901 California Ave., Palo Alto, CA 94304. Phone: (650) 496-1181. Fax: (650) 496-1200. E-mail: lees{at}dnax.org.
 |
REFERENCES |
| 1.
|
Aagaard, L.,
J. Lukas,
J. Bartkova,
A.-A. Kjerulff,
M. Strauss, and J. Bartek.
1995.
Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
Int. J. Cancer
61:115-120[Medline].
|
| 2.
|
Alcorta, D.,
Y. Xiong,
D. Phelps,
G. Hannon,
D. Beach, and J. Barrett.
1996.
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Proc. Natl. Acad. Sci. USA
93:13742-13747[Abstract/Free Full Text].
|
| 3.
|
Bates, S.,
L. Bonetta,
D. MacAllan,
D. Parry,
A. Holder,
C. Dickson, and G. Peters.
1994.
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct set of the cyclin-dependent kinases that associate with cyclin D1.
Oncogene
9:71-79[Medline].
|
| 4.
|
Bates, S.,
D. Parry,
L. Bonetta,
K. Vousden,
C. Dickson, and G. Peters.
1994.
Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein.
Oncogene
9:1633-1640[Medline].
|
| 5.
|
Brookes, S.,
G. Lammie,
E. Schuuring,
C. de Boer,
R. Michalides,
C. Dickson, and G. Peters.
1993.
Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1.
Genes Chromosomes Cancer
6:222-231[Medline].
|
| 6.
|
Dai, K.,
R. Kobayashi, and D. Beach.
1996.
Physical interaction of mammalian CDC37 with CDK4.
J. Biol. Chem.
271:22030-22034[Abstract/Free Full Text].
|
| 7.
|
El-Deiry, W. S.,
T. Tokino,
V. E. Velculescu,
D. B. Levy,
R. Parsons,
J. M. Trent,
D. Lin,
W. E. Mercer,
K. W. Kinzler, and B. Vogelstein.
1993.
WAF1, a potential mediator of p53 tumor suppression.
Cell
75:817-825[Medline].
|
| 8.
|
Gu, Y.,
C. W. Turck, and D. O. Morgan.
1993.
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.
Nature
366:707-710[Medline].
|
| 9.
|
Guan, K.-L.,
C. W. Jenkins,
Y. Li,
M. A. Nichols,
X. Wu,
C. L. O'Keefe,
A. G. Matera, and Y. Xiong.
1994.
Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor correlates with wild-type pRb function.
Genes Dev.
8:2939-2952[Abstract/Free Full Text].
|
| 10.
|
Guan, K.-L.,
C. W. Jenkins,
Y. Li,
C. L. O'Keefe,
S. Noh,
X. Wu,
M. Zariwala,
A. G. Matera, and Y. Xiong.
1996.
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.
Mol. Biol. Cell
7:57-70[Abstract].
|
| 11.
|
Hall, M., and G. Peters.
1996.
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.
Adv. Cancer Res.
68:67-108[Medline].
|
| 12.
|
Hannon, G. J., and D. Beach.
1994.
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.
Nature
371:257-261[Medline].
|
| 13.
|
Hara, E.,
R. Smith,
D. Parry,
H. Tahara,
S. Stone, and G. Peters.
1996.
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.
Mol. Cell. Biol.
16:859-867[Abstract].
|
| 14.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 15.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interactting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
75:805-816[Medline].
|
| 16.
|
Harper, J. W.,
S. J. Elledge,
K. Keyomarsi,
B. Dynlacht,
L.-H. Tsai,
P. Zhang,
S. Dobrowolski,
C. Bai,
L. Connell-Crowley,
E. Swindell,
M. P. Fox, and N. Wei.
1995.
Inhibition of cyclin-dependent kinases by p21.
Mol. Biol. Cell
6:387-400[Abstract].
|
| 17.
|
He, J.,
J. R. Allen,
V. P. Collins,
T. M. Allalunis,
R. Godbout,
R. R. Day, and C. D. James.
1994.
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
Cancer Res.
54:5804-5807[Abstract/Free Full Text].
|
| 18.
|
Hirai, H.,
M. F. Roussel,
J.-Y. Kato,
R. A. Ashmun, and C. J. Sherr.
1995.
Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.
Mol. Cell. Biol.
15:2672-2681[Abstract].
|
| 19.
|
Koh, J.,
G. H. Enders,
B. D. Dynlacht, and E. Harlow.
1995.
Tumor-derived p16 alleles encoding proteins defective in cell cycle inhibition.
Nature
375:506-510[Medline].
|
| 20.
|
LaBaer, J.,
M. Garrett,
L. Stevenson,
J. Slingerland,
C. Sandhu,
H. Chou,
A. Fattaey, and E. Harlow.
1997.
New functional activities for the p21 family of CDK inhibitors.
Genes Dev.
11:847-862[Abstract/Free Full Text].
|
| 21.
|
Lammie, G.,
V. Fantl,
R. Smith,
E. Schuuring,
S. Brookes,
R. Michalides,
C. Dickson,
A. Arnold, and G. Peters.
1991.
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.
Oncogene
6:439-444[Medline].
|
| 22.
|
Lee, M. H.,
I. Reynisdottir, and J. Massague.
1995.
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
Genes Dev.
9:639-649[Abstract/Free Full Text].
|
| 23.
|
Liu, Y.,
J. Martindale,
M. Gorospe, and N. Holbrook.
1996.
Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway.
Cancer Res.
56:31-35[Abstract/Free Full Text].
|
| 24.
|
Lukas, J.,
J. Bartkova,
M. Rohde,
M. Strauss, and J. Bartek.
1995.
Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Mol. Cell. Biol.
15:2600-2611[Abstract].
|
| 25.
|
Lukas, J.,
D. Parry,
L. Aagard,
D. J. Mann,
J. Bartkova,
M. Strauss,
G. Peters, and J. Bartek.
1995.
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16.
Nature
375:503-506[Medline].
|
| 26.
|
Maelandsmo, G.,
J. Berner,
V. Florenes,
A. Forus,
E. Hovig,
O. Fodstad, and O. Myklebost.
1995.
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas relationship to amplification and mRNA levels of CDK4 and CCND1.
Br. J. Cancer
72:393-398[Medline].
|
| 27.
|
Mahony, D.,
D. Parry, and E. Lees.
1998.
Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells.
Oncogene
16:603-611[Medline].
|
| 28.
|
Matsuoka, S.,
M. C. Edwards,
C. Bai,
S. Parker,
P. Zhang,
A. Baldini,
J. W. Harper, and S. J. Elledge.
1995.
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Genes Dev.
9:650-662[Abstract/Free Full Text].
|
| 29.
|
Matsushime, H.,
M. E. Ewen,
D. K. Strom,
J.-Y. Kato,
S. K. Hanks,
M. F. Roussel, and C. J. Sherr.
1992.
Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type cyclins.
Cell
71:323-334[Medline].
|
| 30.
|
Matsushime, H.,
D. E. Quelle,
S. A. Shurtleff,
M. Shibuya,
C. J. Sherr, and J.-Y. Kato.
1994.
D-type cyclin-dependent kinase activity in mammalian cells.
Mol. Cell. Biol.
14:2066-2076[Abstract/Free Full Text].
|
| 31.
|
Matsushime, H.,
M. F. Roussel,
R. A. Ashmun, and C. J. Sherr.
1991.
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle.
Cell
65:701-713[Medline].
|
| 32.
|
Meyerson, M., and E. Harlow.
1994.
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
Mol. Cell. Biol.
14:2077-2086[Abstract/Free Full Text].
|
| 33.
|
Musgrove, E.,
A. Swarbrick,
C. S. Lee,
A. L. Cornish, and R. Sutherland.
1998.
Mechanisms of cyclin-dependent kinase inactivation by progestins.
Mol. Cell. Biol.
18:1812-1825[Abstract/Free Full Text].
|
| 34.
|
Noda, A.,
Y. Ning,
S. F. Venable,
O. M. Pereira-Smith, and J. R. Smith.
1994.
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.
Exp. Cell Res.
211:90-98[Medline].
|
| 35.
|
Otterson, G. A.,
R. A. Kratzke,
A. Coxon,
Y. W. Kim, and F. J. Kaye.
1994.
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
Oncogene
9:3375-3378[Medline].
|
| 36.
|
Palmero, I.,
B. McConnell,
D. Parry,
S. Brookes,
E. Hara,
S. Bates,
P. Jat, and G. Peters.
1997.
Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status.
Oncogene
15:495-503[Medline].
|
| 37.
|
Pardee, A.
1974.
A restriction point for control of normal animal cell proliferation.
Proc. Natl. Acad. Sci. USA
71:1286-1290[Abstract/Free Full Text].
|
| 38.
|
Parry, D.,
S. Bates,
D. J. Mann, and G. Peters.
1995.
Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
EMBO J.
14:503-511[Medline].
|
| 39.
|
Parry, D., and G. Peters.
1996.
Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Mol. Cell. Biol.
16:3844-3852[Abstract].
|
| 40.
|
Polyak, K.,
M. H. Lee,
B. H. Erdjument,
A. Koff,
J. M. Roberts,
P. Tempst, and J. Massague.
1994.
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.
Cell
78:59-66[Medline].
|
| 41.
|
Schmidt, E. E.,
K. Ichimura,
G. Reifenberger, and V. P. Collins.
1994.
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Cancer Res.
54:6321-6324[Abstract/Free Full Text].
|
| 42.
|
Serrano, M.,
G. J. Hannon, and D. Beach.
1993.
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Nature
366:704-707[Medline].
|
| 43.
|
Sewing, A.,
B. Wiseman,
A. Lloyd, and H. Land.
1997.
High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1.
Mol. Cell. Biol.
17:5588-5597[Abstract].
|
| 44.
|
Sherr, C. J.
1996.
Cancer cell cycles.
Science
274:1672-1677[Abstract/Free Full Text].
|
| 45.
|
Sherr, C. J.
1994.
G1 phase progression: cycling on cue.
Cell
79:551-555[Medline].
|
| 46.
|
Sherr, C. J.
1993.
Mammalian G1 cyclins.
Cell
73:1059-1065[Medline].
|
| 47.
|
Stepanova, L.,
X. Leng,
S. B. Parker, and J. W. Harper.
1996.
Mammalian p50cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.
Genes Dev.
10:1491-1502[Abstract/Free Full Text].
|
| 48.
|
Toyoshima, H., and T. Hunter.
1994.
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.
Cell
78:67-74[Medline].
|
| 49.
|
Wang, J.,
K. Guo,
K. Wills, and K. Walsh.
1997.
Rb functions to inhibit apoptosis during myocyte differentiation.
Cancer Res.
57:351-354[Abstract/Free Full Text].
|
| 50.
|
Wolfel, T.,
M. Hauer,
J. Schneider,
M. Serrano,
C. Wolfel,
E. Klehmann-Hieb,
E. De Plaen,
T. Hankeln,
K. Meyer zum Buschenfelde, and D. Beach.
1995.
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
Science
269:1281-1284[Abstract/Free Full Text].
|
| 51.
|
Woods, D.,
D. Parry,
H. Cherwinski,
E. Bosch,
E. Lees, and M. McMahon.
1997.
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1.
Mol. Cell. Biol.
17:5598-5611[Abstract].
|
| 52.
|
Xiong, Y.,
G. J. Hannon,
H. Zhang,
D. Casso,
R. Kobayashi, and D. Beach.
1993.
p21 is a universal inhibitor of cyclin kinases.
Nature
366:701-704[Medline].
|
| 53.
|
Xiong, Y.,
H. Zhang, and D. Beach.
1992.
D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA.
Cell
71:505-514[Medline].
|
Molecular and Cellular Biology, March 1999, p. 1775-1783, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Geest, C. R., Buitenhuis, M., Groot Koerkamp, M. J. A., Holstege, F. C. P., Vellenga, E., Coffer, P. J.
(2009). Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors. Blood
114: 3402-3412
[Abstract]
[Full Text]
-
Day, P. J., Cleasby, A., Tickle, I. J., O'Reilly, M., Coyle, J. E., Holding, F. P., McMenamin, R. L., Yon, J., Chopra, R., Lengauer, C., Jhoti, H.
(2009). Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl. Acad. Sci. USA
106: 4166-4170
[Abstract]
[Full Text]
-
Wu, W., Slastad, H., de la Rosa Carrillo, D., Frey, T., Tjonnfjord, G., Boretti, E., Aasheim, H.-C., Horejsi, V., Lund-Johansen, F.
(2009). Antibody Array Analysis with Label-based Detection and Resolution of Protein Size. Mol. Cell. Proteomics
8: 245-257
[Abstract]
[Full Text]
-
James, M. K., Ray, A., Leznova, D., Blain, S. W.
(2008). Differential Modification of p27Kip1 Controls Its Cyclin D-cdk4 Inhibitory Activity. Mol. Cell. Biol.
28: 498-510
[Abstract]
[Full Text]
-
Jones, R., Ruas, M., Gregory, F., Moulin, S., Delia, D., Manoukian, S., Rowe, J., Brookes, S., Peters, G.
(2007). A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6. Cancer Res.
67: 9134-9141
[Abstract]
[Full Text]
-
Ruas, M., Gregory, F., Jones, R., Poolman, R., Starborg, M., Rowe, J., Brookes, S., Peters, G.
(2007). CDK4 and CDK6 Delay Senescence by Kinase-Dependent and p16INK4a-Independent Mechanisms. Mol. Cell. Biol.
27: 4273-4282
[Abstract]
[Full Text]
-
Leisenfelder, S. A., Moffat, J. F.
(2006). Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.. J. Virol.
80: 5577-5587
[Abstract]
[Full Text]
-
Goulvestre, C., Chereau, C., Nicco, C., Mouthon, L., Weill, B., Batteux, F.
(2005). A Mimic of p21WAF1/CIP1 Ameliorates Murine Lupus. J. Immunol.
175: 6959-6967
[Abstract]
[Full Text]
-
Gysin, S., Lee, S.-H., Dean, N. M., McMahon, M.
(2005). Pharmacologic Inhibition of RAF->MEK->ERK Signaling Elicits Pancreatic Cancer Cell Cycle Arrest Through Induced Expression of p27Kip1. Cancer Res.
65: 4870-4880
[Abstract]
[Full Text]
-
Van Dross, R., Yao, S., Asad, S., Westlake, G., Mays, D. J., Barquero, L., Duell, S., Pietenpol, J. A., Browning, P. J.
(2005). Constitutively Active K-cyclin/cdk6 Kinase in Kaposi Sarcoma-Associated Herpesvirus-Infected Cells. JNCI J Natl Cancer Inst
97: 656-666
[Abstract]
[Full Text]
-
White, J., Stead, E., Faast, R., Conn, S., Cartwright, P., Dalton, S.
(2005). Developmental Activation of the Rb-E2F Pathway and Establishment of Cell Cycle-regulated Cyclin-dependent Kinase Activity during Embryonic Stem Cell Differentiation. Mol. Biol. Cell
16: 2018-2027
[Abstract]
[Full Text]
-
Rowell, E. A., Walsh, M. C., Wells, A. D.
(2005). Opposing Roles for the Cyclin-Dependent Kinase Inhibitor p27kip1 in the Control of CD4+ T Cell Proliferation and Effector Function. J. Immunol.
174: 3359-3368
[Abstract]
[Full Text]
-
Merched, A. J., Chan, L.
(2004). Absence of p21Waf1/Cip1/Sdi1 Modulates Macrophage Differentiation and Inflammatory Response and Protects Against Atherosclerosis. Circulation
110: 3830-3841
[Abstract]
[Full Text]
-
Box, A. H., Demetrick, D. J.
(2004). Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis
25: 2325-2335
[Abstract]
[Full Text]
-
Kahl, C. R., Means, A. R.
(2004). Regulation of Cyclin D1/Cdk4 Complexes by Calcium/Calmodulin-dependent Protein Kinase I. J. Biol. Chem.
279: 15411-15419
[Abstract]
[Full Text]
-
Kahl, C. R., Means, A. R.
(2004). Calcineurin Regulates Cyclin D1 Accumulation in Growth-stimulated Fibroblasts. Mol. Biol. Cell
15: 1833-1842
[Abstract]
[Full Text]
-
Hendricks, K. B., Shanahan, F., Lees, E.
(2004). Role for BRG1 in Cell Cycle Control and Tumor Suppression. Mol. Cell. Biol.
24: 362-376
[Abstract]
[Full Text]
-
Esposito, V, Baldi, A, Tonini, G, Vincenzi, B, Santini, M, Ambrogi, V, Mineo, T C, Persichetti, P, Liuzzi, G, Montesarchio, V, Wolner, E, Baldi, F, Groeger, A M
(2004). Analysis of cell cycle regulator proteins in non-small cell lung cancer. J. Clin. Pathol.
57: 58-63
[Abstract]
[Full Text]
-
Dupont, J., Karas, M., LeRoith, D.
(2003). The Cyclin-dependent Kinase Inhibitor p21CIP/WAF Is a Positive Regulator of Insulin-like Growth Factor I-induced Cell Proliferation in MCF-7 Human Breast Cancer Cells. J. Biol. Chem.
278: 37256-37264
[Abstract]
[Full Text]
-
Paternot, S., Coulonval, K., Dumont, J. E., Roger, P. P.
(2003). Cyclic AMP-dependent Phosphorylation of Cyclin D3-bound CDK4 Determines the Passage through the Cell Cycle Restriction Point in Thyroid Epithelial Cells. J. Biol. Chem.
278: 26533-26540
[Abstract]
[Full Text]
-
Diehl, J. A., Yang, W., Rimerman, R. A., Xiao, H., Emili, A.
(2003). Hsc70 Regulates Accumulation of Cyclin D1 and Cyclin D1-Dependent Protein Kinase. Mol. Cell. Biol.
23: 1764-1774
[Abstract]
[Full Text]
-
Gump, J., Stokoe, D., McCormick, F.
(2003). Phosphorylation of p16INK4A Correlates with Cdk4 Association. J. Biol. Chem.
278: 6619-6622
[Abstract]
[Full Text]
-
Pavenstadt, H., Kriz, W., Kretzler, M.
(2003). Cell Biology of the Glomerular Podocyte. Physiol. Rev.
83: 253-307
[Abstract]
[Full Text]
-
Obaya, A. J., Kotenko, I., Cole, M. D., Sedivy, J. M.
(2002). The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 to Facilitate the Activation of Cdk4/6 and Early G1 Phase Progression. J. Biol. Chem.
277: 31263-31269
[Abstract]
[Full Text]
-
Rodriguez-Puebla, M. L., Miliani de Marval, P. L., LaCava, M., Moons, D. S., Kiyokawa, H., Conti, C. J.
(2002). cdk4 Deficiency Inhibits Skin Tumor Development but Does Not Affect Normal Keratinocyte Proliferation. Am. J. Pathol.
161: 405-411
[Abstract]
[Full Text]
-
Olashaw, N., Pledger, W. J.
(2002). Paradigms of Growth Control: Relation to Cdk Activation. Sci Signal
2002: re7-re7
[Abstract]
[Full Text]
-
Leng, X., Noble, M., Adams, P. D., Qin, J., Harper, J. W.
(2002). Reversal of Growth Suppression by p107 via Direct Phosphorylation by Cyclin D1/Cyclin-Dependent Kinase 4. Mol. Cell. Biol.
22: 2242-2254
[Abstract]
[Full Text]
-
Skildum, A. J., Mukherjee, S., Conrad, S. E.
(2002). The Cyclin-dependent Kinase Inhibitor p21WAF1/Cip1 Is an Antiestrogen-regulated Inhibitor of Cdk4 in Human Breast Cancer Cells. J. Biol. Chem.
277: 5145-5152
[Abstract]
[Full Text]
-
Nelsen, C. J., Rickheim, D. G., Timchenko, N. A., Stanley, M. W., Albrecht, J. H.
(2001). Transient Expression of Cyclin D1 Is Sufficient to Promote Hepatocyte Replication and Liver Growth in Vivo. Cancer Res.
61: 8564-8568
[Abstract]
[Full Text]
-
Kovalev, G. I., Franklin, D. S., Coffield, V. M., Xiong, Y., Su, L.
(2001). An Important Role of CDK Inhibitor p18INK4c in Modulating Antigen Receptor-Mediated T Cell Proliferation. J. Immunol.
167: 3285-3292
[Abstract]
[Full Text]
-
Miliani de Marval, P. L., Gimenez-Conti, I. B., LaCava, M., Martinez, L. A., Conti, C. J., Rodriguez-Puebla, M. L.
(2001). Transgenic Expression of Cyclin-Dependent Kinase 4 Results in Epidermal Hyperplasia, Hypertrophy, and Severe Dermal Fibrosis. Am. J. Pathol.
159: 369-379
[Abstract]
[Full Text]
-
Hu, G., Lee, H., Price, S. M., Shen, M. M., Abate-Shen, C.
(2001). Msx homeobox genes inhibit differentiation through upregulation of cyclin D1. Development
128: 2373-2384
[Abstract]
[Full Text]
-
Gump, J., Turner, S., Koh, J.
(2001). The COOH Terminus of p18INK4C Distinguishes Function from p16INK4A. Cancer Res.
61: 3863-3868
[Abstract]
[Full Text]
-
Schmidt, B. A., Rose, A., Steinhoff, C., Strohmeyer, T., Hartmann, M., Ackermann, R.
(2001). Up-Regulation of Cyclin-dependent Kinase 4/Cyclin D2 Expression but Down-Regulation of Cyclin-dependent Kinase 2/Cyclin E in Testicular Germ Cell Tumors. Cancer Res.
61: 4214-4221
[Abstract]
[Full Text]
-
Bagui, T. K., Jackson, R. J., Agrawal, D., Pledger, W. J.
(2000). Analysis of Cyclin D3-cdk4 Complexes in Fibroblasts Expressing and Lacking p27kip1 and p21cip1. Mol. Cell. Biol.
20: 8748-8757
[Abstract]
[Full Text]
-
Hsieh, F. F., Barnett, L. A., Green, W. F., Freedman, K., Matushansky, I., Skoultchi, A. I., Kelley, L. L.
(2000). Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27Kip1 and inactivation of cdk2 kinase. Blood
96: 2746-2754
[Abstract]
[Full Text]
-
Hartmann, W., Waha, A., Koch, A., Goodyer, C. G., Albrecht, S., von Schweinitz, D., Pietsch, T.
(2000). p57KIP2 Is Not Mutated in Hepatoblastoma but Shows Increased Transcriptional Activity in a Comparative Analysis of the Three Imprinted Genes p57KIP2, IGF2, and H19. Am. J. Pathol.
157: 1393-1403
[Abstract]
[Full Text]
-
Brantley, M. A. Jr., Harbour, J. W.
(2000). Inactivation of Retinoblastoma Protein in Uveal Melanoma by Phosphorylation of Sites in the COOH-Terminal Region. Cancer Res.
60: 4320-4323
[Abstract]
[Full Text]
-
Stepanova, L., Finegold, M., DeMayo, F., Schmidt, E. V., Harper, J. W.
(2000). The Oncoprotein Kinase Chaperone CDC37 Functions as an Oncogene in Mice and Collaborates with Both c-myc and Cyclin D1 in Transformation of Multiple Tissues. Mol. Cell. Biol.
20: 4462-4473
[Abstract]
[Full Text]
-
O'Farrell, A.-M., Parry, D. A., Zindy, F., Roussel, M. F., Lees, E., Moore, K. W., Mui, A. L.-F.
(2000). Stat3-Dependent Induction of p19INK4D by IL-10 Contributes to Inhibition of Macrophage Proliferation. J. Immunol.
164: 4607-4615
[Abstract]
[Full Text]
-
Swarbrick, A., Lee, C. S. L., Sutherland, R. L., Musgrove, E. A.
(2000). Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells. Mol. Cell. Biol.
20: 2581-2591
[Abstract]
[Full Text]
-
Liu, J.-S., Kuo, S.-R., McHugh, M. M., Beerman, T. A., Melendy, T.
(2000). Adozelesin Triggers DNA Damage Response Pathways and Arrests SV40 DNA Replication through Replication Protein A Inactivation. J. Biol. Chem.
275: 1391-1397
[Abstract]
[Full Text]
-
Zindy, F., van Deursen, J., Grosveld, G., Sherr, C. J., Roussel, M. F.
(2000). INK4d-Deficient Mice Are Fertile Despite Testicular Atrophy. Mol. Cell. Biol.
20: 372-378
[Abstract]
[Full Text]
-
Chen, D., Heath, V., O'Garra, A., Johnston, J., McMahon, M.
(1999). Sustained Activation of the Raf-MEK-ERK Pathway Elicits Cytokine Unresponsiveness in T Cells. J. Immunol.
163: 5796-5805
[Abstract]
[Full Text]
-
Sugimoto, M., Nakamura, T., Ohtani, N., Hampson, L., Hampson, I. N., Shimamoto, A., Furuichi, Y., Okumura, K., Niwa, S., Taya, Y., Hara, E.
(1999). Regulation of CDK4 activity by a novel CDK4-binding protein, p34SEI-1. Genes Dev.
13: 3027-3033
[Abstract]
[Full Text]
-
Estanyol, J. M., Jaumot, M., Casanovas, O., Rodriguez-Vilarrupla, A., Agell, N., Bachs, O.
(1999). The Protein SET Regulates the Inhibitory Effect of p21Cip1 on Cyclin E-Cyclin-dependent Kinase 2 Activity. J. Biol. Chem.
274: 33161-33165
[Abstract]
[Full Text]
-
Grossel, M. J., Baker, G. L., Hinds, P. W.
(1999). cdk6 Can Shorten G1 Phase Dependent upon the N-terminal INK4 Interaction Domain. J. Biol. Chem.
274: 29960-29967
[Abstract]
[Full Text]
-
Warner, B. J., Blain, S. W., Seoane, J., Massague, J.
(1999). Myc Downregulation by Transforming Growth Factor beta Required for Activation of the p15Ink4b G1 Arrest Pathway. Mol. Cell. Biol.
19: 5913-5922
[Abstract]
[Full Text]
-
Chen, D., Guo, K., Yang, J., Frazier, W. A., Isner, J. M., Andres, V.
(1999). Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21Cip1/WAF1. Am. J. Physiol. Heart Circ. Physiol.
277: H1100-H1106
[Abstract]
[Full Text]
-
Sherr, C. J., Roberts, J. M.
(1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev.
13: 1501-1512
[Full Text]
-
Murai, T., Nakagawa, Y., Maeda, H., Terada, K.
(2001). Altered Regulation of Cell Cycle Machinery Involved in Interleukin-1-induced G1 and G2 Phase Growth Arrest of A375S2 Human Melanoma Cells. J. Biol. Chem.
276: 6797-6806
[Abstract]
[Full Text]
-
Matushansky, I., Radparvar, F., Skoultchi, A. I.
(2000). Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. USA
97: 14317-14322
[Abstract]
[Full Text]